Biogen Inc (BIIB)

Biogen Shares Surge After Positive Mid-Stage Alzheimer’s Trial ResultsMay 14, 2026 10:08 AM
IH Market News Biogen (NASDAQ:BIIB) shares jumped 10% on Thursday after the company released encouraging Phase 2 data for diranersen, its experimental Alzheimer’s treatment targeting tau protein accumulation.The results came from the company’s CELIA study, which evaluated the therapy in patients with early-stage Alzheimer’s disease. Trial Shows Reductions in Tau Pathology Biogen said diranersen produced significant reductions in tau pathology across all dose levels tested.The findings were consistent with data previously observed in an earlier Phase 1b trial.The treatment reduced both cerebrospinal fluid tau levels and tau pathology measured through positron emission tomography imaging, with reductions maintained throughout the dosing period. Cognitive Decline Slowed Across Tested Doses Pre-specified analyses of cognitive endpoints showed slowing of clinical decline across all studied doses.According to the company, the most notable benefit was observed with the lowest dose of 60 mg administered every 24 weeks.However, the study did not achieve its primary endpoint, which evaluated dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes at Week 76. Study Included More Than 400 Participants The 18-month CELIA study enrolled 416 participants diagnosed with either mild cognitive impairment related to Alzheimer’s disease or mild Alzheimer’s dementia.Participants had not previously received anti-amyloid therapies.Researchers evaluated three dosing regimens during the study: 60 mg every 24 weeks 115 mg every 24 weeks 115 mg every 12 weeks Safety Profile Largely Consistent With Earlier Study Biogen said the safety and tolerability profile of diranersen was generally in line with results from the earlier Phase 1b study.The frequency of adverse events was similar across dose groups, although the highest-dose group experienced a greater number of serious adverse events. Biogen Plans Registrational Development The company said it intends to move diranersen into registrational development and plans to discuss the next regulatory steps with health authorities.The U.S. Food and Drug Administration granted Fast Track designation to diranersen for Alzheimer’s disease treatment in 2025.Diranersen is an antisense oligonucleotide designed to reduce production of tau protein.Unlike therapies targeting only extracellular tau, diranersen aims to reduce both extracellular and intracellular tau.Biogen said additional data from the study will be presented at the Alzheimer’s Association International Conference 2026. Analysts View Advancement Decision as Positive Signal Paul Matteis of Stifel said the company’s decision to continue development despite missing the primary endpoint reflects strong internal confidence in the program.“We would be surprised if they were advancing this on efficacy data that looks worse than the amyloid drugs,” Matteis wrote in a note to clients. “The ’bar’ for advancing this shouldn’t necessarily be statistical significance, because there is still a lot we don’t know around the right population to test the tau thesis.”Matteis also noted that under chief executive Chris Viehbacher, Biogen has aggressively reduced exposure to higher-risk research projects, suggesting management likely sees meaningful potential in the therapy. Dose Response Raises Questions for Investors One of the key discussion points for investors is the study’s non-linear dose response pattern.Typically, higher doses are expected to deliver stronger efficacy, but the CELIA study showed the greatest cognitive benefit at the lowest 60 mg dose rather than at the higher 115 mg levels.Matteis described the issue as an “open question,” suggesting it is theoretically possible that reducing tau levels too aggressively could create offsetting negative effects, although he stressed that conclusion remains speculative until more detailed data becomes available.Biogen stock price Original: Biogen Shares Surge After Positive Mid-Stage Alzheimer’s Trial Results

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's DiseaseMay 8, 2026 2:30 AM
PR Newswire (US) TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.   As part of the ongoing review process, the agency requested additional information and has determined that it constituted a major amendment to the sBLA, extending the PDUFA date to allow sufficient time for a full review of the additional materials. The FDA has not raised any concerns to date regarding the approvability of LEQEMBI IQLIK as a starting dose.Eisai and Biogen believe that the comprehensive clinical data package evaluating subcutaneous administration of LEQEMBI across multiple studies and dosing regimens strongly supports the potential use of LEQEMBI IQLIK for initiation therapy, following FDA approval of the subcutaneous maintenance dosing regimen on August 26, 2025.LEQEMBI has been approved by more than 50 regulatory authorities worldwide, reflecting broad regulatory confidence in LEQEMBI as a treatment option for early Alzheimer's disease.Eisai and Biogen look forward to ongoing discussions with the FDA as the review progresses and are committed to bringing this important advancement to patients and care partners as quickly as possible to provide greater flexibility and choice in how anti-amyloid treatment is delivered.INDICATION
LEQEMBI® is indicated for the treatment of Alzheimer's disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.IMPORTANT SAFETY INFORMATIONWARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA)Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI.Apolipoprotein E e4 (ApoE e4) Homozygotes: Patients who are ApoE e4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE e4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE e4 homozygotes and at higher risk for ARIA.Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI.CONTRAINDICATION
Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.WARNINGS AND PRECAUTIONS
Amyloid-Related Imaging Abnormalities
Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.Incidence of ARIA
Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.Incidence of ICH
ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.Risk Factors of ARIA and ICH
ApoE e4 Carrier Status
Of the patients taking LEQEMBI, 16% were ApoE e4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE e4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE e4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE e4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE e4 carriers and noncarriers.Radiographic Findings of CAA
Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE e4 allele is also associated with CAA.The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.Concomitant Antithrombotic or Thrombolytic Medication
In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.Radiographic Severity With LEQEMBI
Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE e4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE e4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).Monitoring and Dose Management Guidelines
Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.Hypersensitivity Reactions
Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.Infusion-Related Reactions (IRRs)
IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.ADVERSE REACTIONSThe most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%)Safety profile of LEQEMBI IQLIK for maintenance treatment was similar to LEQEMBI infusion. Patients who received LEQEMBI IQLIK experienced localized and systemic (less frequent) injection-related reactions (mild to moderate in severity)LEQEMBI (lecanemab-irmb) is available:Intravenous infusion: 100 mg/mLSubcutaneous injection: 200 mg/mLPlease see full Prescribing Information for LEQEMBI, including Boxed WARNING.MEDIA CONTACTS
Eisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Inc. (U.S.)Julie Edelman+1-862-213-5915Julie_Edelman@eisai.comBiogen Inc.Madeleine Shin +1-781-464-3260public.affairs@biogen.com

INVESTOR CONTACTS
Eisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.comNotes to EditorsAbout lecanemab (generic name, brand name: LEQEMBI®)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aß).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About Protofibrils
Protofibrils are thought to be the most toxic Aß species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms. The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aß plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD.About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q, Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.  View original content to download multimedia:https://www.prnewswire.com/news-releases/update-on-fda-priority-review-of-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-as-a-starting-dose-for-early-alzheimers-disease-302766585.htmlSOURCE Eisai Co., Ltd. Original: Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600May 7, 2026 6:01 PM
PR Newswire (US) NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Family Solutions Inc. (NYSE: BFAM) will replace Tri Pointe Homes Inc. (NYSE: TPH). Sumitomo Forestry Group (TSE: 1911) is acquiring Tri Pointe Homes in a deal expected to close soon, pending final closing conditions.Remitly Global Inc. (NASD: RELY) will replace Apellis Pharmaceuticals Inc. (NASD: APLS). S&P 500 constituent Biogen Inc. (NASD: BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing conditions.Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorMay 14, 2026S&P SmallCap 600AdditionBright Horizons Family SolutionsBFAMConsumer DiscretionaryMay 14, 2026S&P SmallCap 600DeletionTri Pointe HomesTPHConsumer DiscretionaryMay 14, 2026S&P SmallCap 600AdditionRemitly GlobalRELYFinancialsMay 14, 2026S&P SmallCap 600DeletionApellis PharmaceuticalsAPLSHealth CareABOUT S&P DOW JONES INDICESS&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.FOR MORE INFORMATION:S&P Dow Jones Indices
index_services@spglobal.comMedia Inquiries
spdji.comms@spglobal.com View original content:https://www.prnewswire.com/news-releases/bright-horizons-family-solutions-and-remitly-global-set-to-join-sp-smallcap-600-302766326.htmlSOURCE S&P Dow Jones Indices Original: Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026March 20, 2026 12:05 PM
PR Newswire (US)

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that new real-world findings from an analysis of long-term treatment persistence and baseline characteristics among people receiving intravenous (IV) lecanemab (generic name, brand name LEQEMBI®), an anti-amyloid-ß (Aß) protofibril antibody, showed that most patients continue with ongoing lecanemab therapy after the initial 18 months of treatment. The analysis was presented at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) in Copenhagen, Denmark, and online.







In real-world clinical practice, patients with chronic diseases who stay on their treatments longer tend to experience better clinical outcomes and higher satisfaction.1,2 Ninety-four percent of patients who completed 18 months of lecanemab treatment in the Phase III Clarity AD study chose to continue maintenance treatment by enrolling in the subsequent open-label, long-term extension (OLE) study. In the OLE of the Clarity AD study, patients continue to benefit from four years of lecanemab treatment compared with the natural course of Alzheimer's disease (Alzheimer's Disease Neuroimaging Initiative: ADNI*).Long-Term Persistence and Patient Characteristics for Lecanemab in Real-World Use in the United States (Presentation: March 20, 17:05 CET)
This analysis is the first time real-world lecanemab data on treatment persistence beyond 18 months has been reported.This study was a retrospective observational analysis using the PurpleLab® CLEAR Claims database, a comprehensive dataset based on medical insurance claims across the United States and was conducted to evaluate the long-term treatment persistence of lecanemab in real-world clinical practice.¦ Patient background and dosing
The analysis population consisted of 10,763 individuals who met the requirement for continuous healthcare encounters, out of the 13,388 individuals recorded in the database who received at least one IV treatment with lecanemab between January 6, 2023 and November 30, 2025. At baseline, the mean age was 73.8 years and 56.5% were female. The most common comorbidities were dyslipidemia (42.2%) and hypertension (36.9%). The mean follow-up duration was 350.9 days. The average number of administrations was 1.7 per month, and the mean dosing interval was 16.4 days (median 14 days), which was generally consistent with the recommended every two weeks dosing.¦ Long-Term persistence results
The time-dependent proportion of patients who remained on lecanemab treatment was evaluated using the Kaplan–Meier method in a subgroup of 371 patients who initiated treatment in 2023 and had 20 months of continuous follow-up, thereby enabling assessment of long-term treatment persistence beyond 18 months. As a result, 78.4% of individuals continued lecanemab treatment at 18 months, 71.7% at 20 months, and 67.3% at 24 months. Of the 78.4% of patients who remained on lecanemab at 18 months, the majority of them continued treatment during the maintenance period beyond 18 months, confirming a high rate of treatment persistence with lecanemab in real-world clinical practice. The patient characteristics and dosing patterns observed in this claims-based analysis were generally similar to those reported in the Clarity AD study. Furthermore, the relatively high treatment adherence observed among individuals suggests that potential delays due to MRI monitoring requirements, adverse events, and other factors did not substantially affect lecanemab dosing.Eisai serves as the lead for lecanemab's development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.[Notes to Editors] About lecanemab (generic name, brand name: LEQEMBI)
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aß).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 7 countries including the U.S., China, the UK, and others, and applications have been filed in 10 countries and regions. The U.S. FDA approved Eisai's Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026. The sBLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of May 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the "Commercial Insurance Innovative Drug List", recently introduced by the National Healthcare Security Administration (NHSA) of China.In the global Phase 3 placebo-controlled, double-blind, parallel-group, randomized Clarity AD core study, the mean change from baseline between the lecanemab treated group and the placebo group after 18 months was -0.45 (P=0.00005) on the primary endpoint of CDR-SB global cognitive and functional scale. To provide context, a change from 0.5 to 1 on the Clinical Dementia Rating (CDR) score domains of Memory, Community Affairs and Home/Hobbies reflects a shift from mild impairment to loss of independence. This can affect a person's ability to be left alone safely, recall recent events, participate in daily activities, manage household tasks, and engage in hobbies and intellectual interests.3,4Over three years of treatment, including both the core study and the OLE, data showed lecanemab demonstrated a reduction in cognitive decline—measured by CDR-SB—of 1.01 points compared to the expected decline observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. This benefit grew more pronounced after four years, with a reduction of 1.75 points. Similarly, when benchmarked against the expected decline in the BioFINDER** cohort, lecanemab showed a reduction of 1.40 points at three years and an even greater reduction of 2.17 points at the four years mark.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.** BioFINDER subjects are similar to Study 301 and ADNI subjects, except all BioFINDER subjects are in the MCI stage and no mild AD subjects are included, and their baseline CDR-SB is lower. BioFINDER is a large-scale, long-term prospective study led by Lund University in Sweden, aiming to establish early. diagnosis and elucidate pathophysiology of neurodegenerative diseases. In addition to AD, the study also focuses on conditions including Parkinson's Disease. Individuals participating in the study undergo regular clinical assessments, cognitive function tests, brain imaging (MRI, Aß PET, Tau PET), and collection of biomarkers from blood and cerebrospinal fluid (CSF).About Protofibrils
Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aß, having a primary role in the cognitive decline associated with this progressive, debilitating condition.5 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aß plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.6About the Collaboration between Eisai and Biogen for AD
Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for AD
Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.
Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab (marketed as LEQEMBI); the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for LEQEMBI (lecanemab) subcutaneous autoinjector (SC-AI); the potential to expand options and reduce healthcare resources by treating Alzheimer's disease at home; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "goal," "guidance," "hope," "intend," "may," "objective," "outlook," "plan," "possible," "potential," "predict," "project," "prospect," "should," "target," "will," "would" or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov.These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.ReferencesGuerci B et al. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Therapy, 2019; 10(2), 437-449.Menditto E et al. Persistence as a robust indicator of medication adherence-related quality and performance. International journal of environmental research and public health, 2021; 18(9), 4872.Cohen S., et al. J Prev Alzheimers Dis.2022;9(3):507-522.Morris JC. Neurology. 1993;43(11):2412-4.Amin L, Harris DA. Aß receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021; 12:3451. doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-ß are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.



View original content to download multimedia:https://www.prnewswire.com/news-releases/results-from-real-world-long-term-treatment-persistence-with-leqembi-lecanemab-irmb-in-the-united-states-presented-at-adpd-2026-302719271.htmlSOURCE Eisai Inc.

Original: Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Biogen shares Phase 1b findings for salanersen in spinal muscular atrophyMarch 11, 2026 11:09 AM
IH Market News
Biogen Inc. (NASDAQ:BIIB) unveiled results from a Phase 1b clinical study evaluating salanersen, an experimental antisense oligonucleotide therapy for spinal muscular atrophy (SMA), during the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on Wednesday.The trial involved 24 children aged between six months and 12 years who continued to show suboptimal clinical outcomes after receiving gene therapy. Each participant received at least two annual doses of salanersen—either 40 mg or 80 mg. According to a press release, all participants were followed for at least one year.Results showed that patients treated with salanersen experienced a 75% drop in neurofilament light chain levels after six months, with the reduction sustained throughout the follow-up period. All 24 participants demonstrated improvements from baseline on at least one clinical endpoint. Twelve patients achieved at least one additional World Health Organization motor milestone, while every participant maintained the milestones they had already reached.The treatment was generally well tolerated at both dosage levels. Among participants receiving the 40 mg dose, the most frequently reported adverse events were upper respiratory tract infections and vomiting. In the 80 mg group, the most common events were fever and upper respiratory infections. Most side effects were classified as mild to moderate.Biogen also outlined the design of its upcoming Phase 3 clinical programme, which will evaluate an 80 mg dose of salanersen across three international studies. The STELLAR-1 study will focus on treatment-naïve infants younger than six weeks. STELLAR-2, a randomized, double-blind, sham-controlled trial, will examine salanersen administered six months after gene therapy in infants. The SOLAR study will evaluate the therapy in adolescents and adults aged 15 to 60 who are either treatment-naïve or previously treated with risdiplam.Screening for STELLAR-1 has already begun. The SOLAR study is expected to launch in the second quarter of 2026, while STELLAR-2 is planned to start in the third quarter of the year.Biogen obtained global development and commercialization rights for salanersen through a licensing agreement with Ionis Pharmaceuticals.Biogen has also drawn attention from several analysts recently. Barclays initiated coverage with an Equalweight rating and a price target of $185. Goldman Sachs maintained a Buy rating and set a $231 price target, citing strong sales of the Alzheimer’s treatment Leqembi. BMO Capital Markets raised its target price to $196, pointing to potential growth for Biogen’s Spinraza therapy. Meanwhile, TD Cowen increased its price target to $215 after the company reported fourth-quarter results that exceeded revenue and earnings expectations.Biogen stock price

Original: Biogen shares Phase 1b findings for salanersen in spinal muscular atrophy

Biogen stock edges higher after Q4 beat and upbeat 2026 earnings guidanceFebruary 6, 2026 9:45 AM
IH Market News
Biogen Inc. (NASDAQ:BIIB) delivered stronger-than-expected results for the fourth quarter of 2025 and paired them with a confident profit outlook for 2026, lifting its shares modestly higher following the announcement.The biotech group reported adjusted earnings of $1.99 per share, comfortably ahead of analyst expectations of $1.61. Revenue totaled $2.28 billion, topping the consensus forecast of $2.21 billion, although this marked a 7% decline from the prior year. Biogen shares rose around 1.4% after the results were released.Performance from newer growth therapies remained a bright spot. Sales from growth products rose 6% year over year in the quarter. Global in-market sales of LEQEMBI reached about $134 million, up 54% from a year earlier, while ZURZUVAE generated roughly $66 million in revenue, reflecting strong uptake. SKYCLARYS also continued to gain traction, with the number of patients on therapy increasing by around 30% during 2025.“Our 2025 performance reflected continued focus on strong execution and financial discipline, driven by our revenue of nearly $1 billion from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, progression of our pipeline, and resilience of our MS franchise,” said Christopher A. Viehbacher, President and Chief Executive Officer.Looking ahead, Biogen forecast adjusted earnings per share of $15.25 to $16.25 for fiscal 2026, above the Street consensus of $14.92. The company cautioned, however, that total revenue is expected to fall by a mid-single-digit percentage versus 2025, as continued declines in multiple sclerosis product sales—excluding VUMERITY—are only partly offset by growth from newer therapies.Biogen stock price

Original: Biogen stock edges higher after Q4 beat and upbeat 2026 earnings guidance

Amazon’s capex surge, Stellantis reset, Bitcoin slide – what’s driving markets: Dow Jones, S&P, Nasdaq, Wall Street FuturesFebruary 6, 2026 5:30 AM
IH Market News
U.S. equity futures edged lower on Friday as weakness in technology stocks persisted. Online retail giant Amazon (NASDAQ:AMZN) unveiled a sharp increase in capital spending, while carmaker Stellantis (NYSE:STLA) flagged a major strategic rethink away from electric vehicles. Bitcoin (COIN:BTCUSD) continued to slide, and oil markets remained focused on the outcome of talks between the United States and Iran.



Amazon plans sharp rise in capital expenditure



Amazon (NASDAQ:AMZN) was among the last major tech groups to report quarterly results after Thursday’s Wall Street close and followed peers in outlining a significant ramp-up in spending on artificial intelligence infrastructure.Chief executive Andy Jassy said Amazon intends to invest $200 billion in expanding its AI capabilities in 2026, implying a more than 50% jump in capital expenditure this year. The scale of the spending increase unsettled investors, pushing the stock sharply lower in after-hours trading.The announcement reinforced expectations that Big Tech is far from easing back on AI investment. The four largest hyperscalers—Amazon, Microsoft, Google and Meta—are now forecast to spend more than $630 billion collectively this year.On the numbers, Amazon posted fourth-quarter 2025 earnings of $1.95 per share on revenue of $213.39 billion, up 13.6% year on year, narrowly missing profit forecasts. Amazon Web Services delivered revenue of $35.6 billion in the December quarter, with sales growth of 24%, its strongest pace in 13 quarters.While AWS represents only around 15–20% of group revenue, it generates more than 60% of Amazon’s operating profit.
“Amazon delivered a slightly mixed picture with strong overall revenue growth and a standout boost from the cloud unit’s much anticipated reacceleration picking up greater speed,” Emarketer principal analyst Sky Canaves said.



U.S. futures slip as Wall Street eyes weekly losses



U.S. stock futures were lower early Friday, extending recent declines as Amazon’s selloff weighed on the broader technology sector. At 03:35 ET, S&P 500 futures were down 0.2%, Nasdaq 100 futures slipped 0.4%, and Dow futures eased 0.1%.Wall Street closed sharply lower on Thursday, with the Nasdaq Composite dropping 1.6%, the S&P 500 falling 1.2% and the Dow Jones Industrial Average shedding more than 500 points. The Nasdaq is on track for its worst weekly performance since early April, down around 4%, while the S&P 500 has lost roughly 2%. The Dow is broadly flat for the week.More corporate results are due later Friday, including updates from Under Armour (NYSE:UAA), Biogen (NASDAQ:BIIB), AutoNation (NYSE:AN) and Philip Morris (NYSE:PM). The U.S. jobs report, originally scheduled for Friday, has been pushed to next week following the resolution of the federal government shutdown.Separately, data from Challenger, Gray & Christmas showed announced layoffs by U.S. employers surged in January to the highest level for the month in 17 years.



Stellantis books major charge in “strategic shift”



Stellantis (NYSE:STLA) said it would take a charge of around €22 billion ($26.5 billion) linked to a reassessment of its electric vehicle strategy, resulting in a preliminary loss of between €19 billion and €21 billion in the second half of 2025.The group said the majority of the write-downs relate to changes in its product roadmap, driven by sharply reduced assumptions for EV demand.
“The charges announced today largely reflect the cost of over-estimating the pace of the energy transition that distanced us from many car buyers’ real-world needs, means and desires,” said Stellantis CEO Antonio Filosa in a statement.The Franco-Italian automaker described the move as a “strategic shift” as it responds to high costs and softer-than-expected EV sales. Stellantis, along with other major European manufacturers such as Volkswagen, has also called for subsidies to support car production in the EU amid pressure from U.S. tariffs and rising competition from China.



Bitcoin heads for steep weekly decline



Bitcoin weakened further on Friday, leaving the world’s largest cryptocurrency on course for a heavy weekly loss as confidence in risk assets continued to fade. Bitcoin fell more than 9% to around $64,730, after earlier touching a 16-month low near $60,100.The digital asset was heading for a third consecutive weekly decline and was down more than 20% over the week. It has also lost over half its value from the record high reached in October and has erased all gains made since President Donald Trump’s election victory in late 2024.Bitcoin has been hit by a broader retreat from speculative assets, with selling pressure intensifying after Trump nominated Kevin Warsh as his preferred candidate for Federal Reserve chair. Warsh has previously opposed the Fed’s asset-purchase programs, and expectations of a leaner central bank balance sheet have weighed on crypto markets.Adding to the pressure, major corporate holder Strategy (NASDAQ:MSTR) reported a much wider fourth-quarter loss on Thursday, largely reflecting declines in the value of its Bitcoin holdings.



Oil prices up, but weekly losses loom ahead of talks



Oil prices rose on Friday but remained on track for their first weekly decline in nearly two months, as investors awaited the outcome of U.S.–Iran talks later in the day. Brent crude climbed 1.3% to $68.38 a barrel, while U.S. West Texas Intermediate gained 1.4% to $64.19.Despite the rebound, Brent was set to finish the week down 3.3% and WTI lower by around 1.8%, with U.S. and Iranian officials due to meet in Oman amid elevated tensions in the Middle East. Markets have been hoping that dialogue between Washington and Tehran could help ease tensions and reduce the risk of wider conflict, prompting traders to remove some geopolitical risk premium from oil prices this week.However, uncertainty remains after reports of disagreement over the scope of the talks, with Iran rejecting U.S. calls to include discussions on its missile program and saying negotiations would be limited to nuclear issues. Iran is a major oil producer and sits next to the Strait of Hormuz, one of the world’s most critical shipping routes for crude.Amazon stock priceStellantis stock priceStrategy stock price

Original: Amazon’s capex surge, Stellantis reset, Bitcoin slide – what’s driving markets: Dow Jones, S&P, Nasdaq, Wall Street Futures

🌿 Multiple Sclerosis: Plant Relief vs. Engineered Immunotherapy
Medical cannabis: Oils, sprays, and edibles are used to ease muscle spasms and nerve pain, marketed as natural symptom management.

Biotech/Pharma: Pharma giants invest in immunotherapies and biologics — highly engineered drugs that target immune cells at the molecular level.

The clash: Cannabis offers accessible, plant-based comfort, while biotech emphasizes cutting-edge science and expensive treatments. $BIIB $MSOS $MJ $TOKE

First, @P_McCulloughMD who is one of the most published people in the world on Covid vaccine myocarditis spoke.

He saw warning signs as early as August of 2021 that the vaccines can cause myocarditis… pic.twitter.com/Gexd9yXOhU— Anna Matson (@AnnaRMatson) May 22, 2025 $BIIB

BIIB, new 52 week low

BIIB new 52 week low

Biib must be out of AD bullets…or actually more like BB’s. With 3-4 20 billion dollar swap trading by HF’s the stock is at multiyear lows. It used to hit $200 and would spring up like clock work.

I hope the validation of our science upon MAA approval at AVXL puts a fork in this company making their pipeline overly insignificant.

BIIB still in bear mode

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

BIIB still in bear mode

Oops…. Another HOD


$10

BIIB Took a little short AH when it's PDUFA decision was mixed
Shorted at 261.50
Closed out AH at 260.87
Not expecting more than a hamburger and fries. BIOGEN INC is huge company and hard to move its dial.

https://stockcharts.com/h-sc/ui?s=BIIB

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

This board is about to light up!

Well Biib and Esaly look to be joined at the hip. And here I thought they were two profitable independent companies. Amazing how they have traded virtually identical as if this is their only ticket left to punch.

And why no run up? Is the gig finally up Mc? Maybe their MM “cried wolf” one too many times.

Who wants to be the lead Buffalo today?
Can you stampede the herd of bio thieves over the $30Billion dollar cliff for the fourth time? Maybe! But you are stealing from treatments and patients and all those who love them.. for nothing..
The best aduscam will ever be is an adjuvant to anavex or cassava..

The BEST..

Don’t do it again .. even if you can..

Please

Funds swapping spit again, nothing new.

Imagine if fda had denied?
Pyrrhic Victory defined

Amen MC. Im surprised at only a 3.5% rise in pps. Wheres the 10-20 billion MC increase enthusiasm like 4 times before? Maybe they will have to PR it again in a week so the market “gets it”.

Ps not short Biogen..
Just long dementia

Investors can make a difference as to what our healthcare system becomes..

You and your decisions affect millions of lives..

Let Blarcamesine , succesful TLD ,
Be the rule of the day for our sick..

See if other drugs help people once their homeostasis is secured..maybe in smaller doses as an adjuvant ..

Anavex’s Blarcamesine works

If you will give a healthy 5 year old an experimental mRNA drug which creates toxic spike proteins in their system..by design! Nonetheless, why wouldn’t you give death sentenced dementia patients a dangerous possibly brain swelling drug that does almost nothing?

The system is broken

This will be the last chance to extricate your financial future from bioscam
And invest in one of these :
Anavex
Cassava
Annovis

Biovie

In that order of magnitude per solution and timing ..in my humble opinion

Or all four..

Will Biogen drop like a rock by or shoot up by 10 billion come Friday? FDA is in a pickle here. Is there an advisory panel this go around or is this who will weigh in come Friday?

What a scam! Older article but will take afew years to play out Im sure.

Biogen Accused of Baiting Patients With Illegal Drug Co-Pays
ByRobert Burnson
September 24, 2021, 9:57 PM EDT

Biogen Inc. was accused by a managed-care provider of illegally boosting sales of its pricey multiple sclerosis drugs by providing them free to patients on a temporary basis and then funneling money to them for co-payments so they can keep taking the medications.

The first part of the scheme involves “seeding” the drugs -- Tysabri, Avonex, and Tecfidera -- to multiple sclerosis sufferers who lacked medical insurance, according to the lawsuit filed Friday by Humana Inc.

After a few months, Biogen encourages the patients to sign up for government-funded healthcare and then funnels “illegal copayment assistance to those same patients under the guise of unrestricted charitable giving,” Humana said.

The money is funneled through a large specialty pharmacy and two medical charities who provide co-pay assistance, according to the suit.

“Given the high costs of the MS drugs here, copays can be thousands of dollars for any single patient,” Humana says in the suit.“But they are a tiny fraction of the total expense for the drugs. This means that if the manufacturer pays the copays itself, it can earn a major return from a minor investment.”

The drugs cost $50,000 to $80,000 a year, according to the suit.

Biogen didn’t respond after regular business hours to a request for comment.

RGEN is on a run while Biogen is stalled.. Both similar companies,

https://www.marketwatch.com/press-release/grabar-law-office-investigates-claims-on-behalf-of-shareholders-of-biogen-inc-biib-after-it-agrees-to-pay-900-million-for-improper-physician-payments-2022-11-30?siteid=bigcharts&dist=bigcharts&tesla=y

Unlike the patients heads, the share price “swelling” for Biogen always goes down. Another difference is Biogens Alzheimer’s amyloid platform never dies, just a few of their patients here and there in their trials.

Alzheimer’s is tough, didnt you know, just a little collateral damage, now hurry up and give me approval!

How does this dead dog bounce?
On swelled brains of course

One last dance?

Wouldnt touch bioscam
But agree seller salmoat out

Biogen (NASDAQ:BIIB) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $265.00 price target on the stock, up previously from $235.00.This represents a 23.7% upside from the current price of $214.28

---- Biotechs are due for a run soon....jmo

Phase 4. How many must suffer to pave the linings? When anavex has safe and proved drug available now?
How hateful the crews that say they care about human beings suffering dementia..

You don’t give a shit

Can you imagine the poor bastards that listened to Corey Renauer of motley fool when he said sell Anavex and buy Biogen a few years back?
Can they sue anyone?

What a cruel and twisted effort that was

All the resources these pumpers stole from legitimate chances to save people with dementia..

How much quicker Anavex and others could have moved without this blockaded fraud in their way..

Oxygen and money hole from hell

Thought they were getting bought out today?

What’s worse is

They knew who anavex was and blew up a chance at a deep relationship through what appears to be a poorly handled MTA ..

Still waiting for Wayne State.. pathetic really..

Arrogance and power smell worse than week old sub Saharan carrion..

Another pump and dump, this time on approval of their drug of all things! Wow, when even approval doesnt work there is some real bad mojo working against you. 3rd or 4 rth cycle of 20 billion that has come and gone. The HFs that own BIIB are making a killing, no pun intended!

$BIIB NEWS!!!! Fasten your SEATBELTS!???????
https://finance.yahoo.com/news/biogen-plans-initiate-phase-3b-113000162.html

Halberd Corp eradicates (for virtually 100%) the main building block (P-TAU) of ALZHEIMER'S DISEASE from CSF in fully patented extracorporeal treatment, experimentation at ASU and YSU. Same treatment applies to Tau, Beta-Amyloid and the inflammatory cytokines IL-6, TNF-alpha and so on

https://www.accesswire.com/viewarticle.aspx?id=663682

Laughable, the pps is one step away from giving up all the fake gains from the announcement of Fda approval for their drug which is still not shown to be efficacious and can be highly toxic for patients including but not limited to death.

OAN Im a little surprised that ihub only allows investors to go back 1 year on the charting….. what gives? Those that forget history are more likely to repeat it. Case in point, I was trying to go back 5 years and look at how Biogen has been overhyped now 3 times for the very close to the exact same amount and has given it all back 2 of the 3 and soon to be 3 for 3 times.

Just an observation.

Pps down $120+ after pumping their bad meds which have no efficacy. Eisai has to break away or go down with the liars. Japanese dont like the bad rep.

STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

By Ed Silverman



The 15-to-0 vote on the Alzheimer's drug Aduhelm amounted to a rebuke of both Biogen and the Food and Drug Administration.

Biogen's Aduhelm stumbles at the starting blocks.

https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/

$BIIB WEEEEEEEEE!!